生物可降解聚合物西罗莫司洗脱支架与耐久聚合物依维莫司洗脱支架在ST段抬高型心肌梗死患者中的比较(BIOSTEMI):一项单盲、前瞻性、随机优效性试验
BIOSTEMI试验在瑞士10家医院纳入1300例接受直接PCI的急性STEMI患者,随机1:1比较生物可降解聚合物西罗莫司洗脱支架与耐久聚合物依维莫司洗脱支架。12个月时靶病变失败在生物可降解聚合物西罗莫司洗脱支架组25/649例(4%),耐久聚合物依维莫司洗脱支架组36/651例(6%),率比0.59(95%贝叶斯可信区间0.37-0.94),优效后验概率0.986;心源性死亡、靶血管心肌再梗死、临床指示的靶病变血运重建及明确支架血栓两组相似。
要点
- 急性STEMI直接PCI患者中,生物可降解聚合物西罗莫司洗脱支架12个月靶病变失败率4%低于耐久聚合物依维莫司洗脱支架的6%。
- 率比0.59(95%贝叶斯可信区间0.37-0.94),优效后验概率0.986。
- 心源性死亡、靶血管心肌再梗死、临床指示的靶病变血运重建及明确支架血栓两组12个月内相似。
核心结论
- 在接受直接PCI的急性STEMI患者中,生物可降解聚合物西罗莫司洗脱支架在1年靶病变失败方面优于耐久聚合物依维莫司洗脱支架。
- 该差异由生物可降解聚合物西罗莫司洗脱支架组缺血驱动的靶病变血运重建减少所驱动。
研究设计与样本
- BIOSTEMI为研究者发起的多中心、前瞻性、单盲、随机优效性试验,在瑞士10家医院开展。
- 纳入18岁及以上因急性STEMI转诊接受直接PCI的患者,按1:1随机分配至生物可降解聚合物西罗莫司洗脱支架或耐久聚合物依维莫司洗脱支架。
- 采用计算机生成分配序列进行中央随机化,区组大小可变(2、4、6),按中心、糖尿病状态及是否存在多支冠状动脉病变分层,并通过安全网络系统隐藏分配。
- 患者和治疗医生知晓分组,结局评估者设盲;主要终点为索引操作后12个月内靶病变失败(心源性死亡、靶血管心肌再梗死[Q波和非Q波]及临床指示的靶病变血运重建的复合终点)。
- 分析以个体参与者为单位,按意向性治疗原则进行;试验注册号ClinicalTrials.gov NCT02579031。
主要发现
- 2016年4月26日至2018年3月9日,随机分配1300例急性心肌梗死患者(1623处病变)至生物可降解聚合物西罗莫司洗脱支架组(649例患者、816处病变)或耐久聚合物依维莫司洗脱支架组(651例患者、806处病变)。
- 12个月时,生物可降解聚合物西罗莫司洗脱支架组614例(95%)患者和耐久聚合物依维莫司洗脱支架组626例(96%)患者有随访数据。
- 主要复合终点靶病变失败在生物可降解聚合物西罗莫司洗脱支架组649例中发生25例(4%),耐久聚合物依维莫司洗脱支架组651例中发生36例(6%)(差值-1.6个百分点;率比0.59,95%贝叶斯可信区间0.37-0.94;优效后验概率0.986)。
- 12个月随访期间,心源性死亡、靶血管心肌再梗死、临床指示的靶病变血运重建及明确支架血栓在两组间相似。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Newer-generation drug-eluting stents that combine ultrathin strut metallic platforms with biodegradable polymers might facilitate vascular healing and improve clinical outcomes in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention (PCI) compared with contemporary thin strut second-generation drug-eluting stents. We did a randomised clinical trial to investigate the safety and efficacy of ultrathin strut biodegradable polymer sirolimus-eluting stents versus thin strut durable polymer everolimus-eluting stents in patients with acute ST-segment elevation myocardial infarction (STEMI) undergoing primary PCI. METHODS: The BIOSTEMI trial was an investigator-initiated, multicentre, prospective, single-blind, randomised superiority trial at ten hospitals in Switzerland. Patients aged 18 years or older with acute STEMI who were referred for primary PCI were eligible to participate. Patients were randomly allocated (1:1) to either biodegradable polymer sirolimus-eluting stents or durable polymer everolimus-eluting stents. Central randomisation was done based on a computer-generated allocation sequence with variable block sizes of 2, 4, and 6, which was stratified by centre, diabetes status, and presence or absence of multivessel coronary artery disease, and concealed using a secure web-based system. Patients and treating physicians were aware of group allocations, whereas outcome assessors were masked to the allocated stent. The experimental stent (Orsiro; Biotronik; Bülach, Switzerland) consisted of an ultrathin strut cobalt-chromium metallic stent platform releasing sirolimus from a biodegradable polymer. The control stent (Xience Xpedition/Alpine; Abbott Vascular, Abbott Park, IL, USA) consisted of a thin strut cobalt-chromium stent platform that releases everolimus from a durable polymer. The primary endpoint was target lesion failure, a composite of cardiac death, target vessel myocardial reinfarction (Q-wave and non-Q-wave), and clinically-indicated target lesion revascularisation, within 12 months of the index procedure. All analyses were done with the individual participant as the unit of analysis and according to the intention-to-treat principle. The trial was registered with ClinicalTrials.gov, number NCT02579031. FINDINGS: Between April 26, 2016, and March 9, 2018, we randomly assigned 1300 patients (1623 lesions) with acute myocardial infarction to treatment with biodegradable polymer sirolimus-eluting stents (649 patients and 816 lesions) or durable polymer everolimus-eluting stents (651 patients and 806 lesions). At 12 months, follow-up data were available for 614 (95%) patients treated with biodegradable polymer sirolimus-eluting stents and 626 (96%) patients treated with durable polymer everolimus-eluting stents. The primary composite endpoint of target lesion failure occurred in 25 (4%) of 649 patients treated with biodegradable polymer sirolimus-eluting stents and 36 (6%) of 651 patients treated with durable polymer everolimus-eluting stents (difference -1·6 percentage points; rate ratio 0·59, 95% Bayesian credibility interval 0·37-0·94; posterior probability of superiority 0·986). Cardiac death, target vessel myocardial reinfarction, clinically-indicated target lesion revascularisation, and definite stent thrombosis were similar between the two treatment groups in the 12 months of follow-up. INTERPRETATION: In patients with acute STEMI undergoing primary PCI, biodegradable polymer sirolimus-eluting stents were superior to durable polymer everolimus-eluting stents with respect to target lesion failure at 1 year. This difference was driven by reduced ischaemia-driven target lesion revascularisation in patients treated with biodegradable polymer sirolimus-eluting stents compared with durable polymer everolimus-eluting stents. FUNDING: Biotronik.
引用
- Iglesias JF, Muller O, Heg D, et al. Biodegradable polymer sirolimus-eluting stents versus durable polymer everolimus-eluting stents in patients with ST-segment elevation myocardial infarction (BIOSTEMI): a single-blind, prospective, randomised superiority trial. Lancet. 2019. PMID: 31488372. doi:10.1016/S0140-6736(19)31877-X
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。